Maxx Orthopedics commenced commercial launch and announced first successful surgeries using its new Libertas® Taper Reduced (TR) Uncemented Femoral Stem.
Libertas TR is a press fit, double tapered stem with Ti-GrowthC® coating offered in standard and distally reduced versions. The stems are available in three neck angles to accommodate patient-specific anatomic requirements and are compatible with Maxx’s existing Libertas Femoral Heads, as well as the Libertas Acetabular Cup. The proximal Ti-GrowthC coating on the implant surface is designed to promote biological integration with bone for longer-term stability, while the geometry of the stem aids in providing a better fit for proximal and distal mismatches.
“[The] Libertas TR is in limited release now, and we expect full commercial release within three months. As a company this launch is particularly invigorating as we continue to battle the challenges posed by COVID-19,” said Ashesh Shah, Chief Executive Officer.
Maxx Orthopedics commenced commercial launch and announced first successful surgeries using its new Libertas® Taper Reduced (TR) Uncemented Femoral Stem.
Libertas TR is a press fit, double tapered stem with Ti-GrowthC® coating offered in standard and distally reduced versions. The stems are available in three neck angles to accommodate...
Maxx Orthopedics commenced commercial launch and announced first successful surgeries using its new Libertas® Taper Reduced (TR) Uncemented Femoral Stem.
Libertas TR is a press fit, double tapered stem with Ti-GrowthC® coating offered in standard and distally reduced versions. The stems are available in three neck angles to accommodate patient-specific anatomic requirements and are compatible with Maxx’s existing Libertas Femoral Heads, as well as the Libertas Acetabular Cup. The proximal Ti-GrowthC coating on the implant surface is designed to promote biological integration with bone for longer-term stability, while the geometry of the stem aids in providing a better fit for proximal and distal mismatches.
“[The] Libertas TR is in limited release now, and we expect full commercial release within three months. As a company this launch is particularly invigorating as we continue to battle the challenges posed by COVID-19,” said Ashesh Shah, Chief Executive Officer.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
Copy to clipboard 
